

5. (Amended) Use according to Claim 1, characterized in that the diseases constitute parasitic diseases, in particular scabies, pediculosis or creeping eruption.

6. (Amended) Use according to Claim 1, characterized in that the diseases affect:

- a) the eye, in particular the lid, conjunctiva or cornea of the eye;
- b) the ear, in particular the exterior of the ear;
- c) the nose, in particular the nasal cavity;
- d) the lips and mucous membranes of the mouth and/or the tongue;
- e) the vulva and/or vagina;
- f) the penis, in particular the glans penis and the prepuce;
- g) the anus;
- h) the nail, in particular the body of the nail, the wall and fold of the nail as well as the root of the nail;
- i) the hair, in particular the hair follicles and the sebaceous glands and
- j) the hands and feet, in particular the spaces between the fingers and toes.

7. (Amended) Use according to Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 0.1 to 20% by weight.

8. (Amended) Use according to Claim 1, characterized in that a tosylchloramide salt is employed, in particular chloramine T.

9. (Amended) Use according to Claim 7, characterized in that the base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.

11. (Amended) Use according to Claim 9, characterized in that the base constitutes a dosed aerosol or a dosed solution.
12. (Amended) Use according to Claim 9, characterized in that the base constitutes a bath water additive.
13. (Amended) Use according to Claim 9, characterized in that the salve is an O/W- or a W/O-emulsion ointment.
- X 3*
- Part B
Cont*
14. (Amended) Use according to Claim 7, characterized in that the base is a cortisone-containing preparation, containing the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 20% by weight.
15. (Amended) Use according to Claim 9, characterized in that the base is a gel, in which are present the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 5% by weight.
16. (Amended) Use according to Claim 9, characterized in that the bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.

Please add the following new claims:

- Part B
Cont*
17. Use according to Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 5 to 15% by weight.
18. Use according to Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 8 to 12% by weight.

- (Handwritten mark)*
- Sub B1 cont*
-
19. Use according to Claim 9, characterized in that the base is a gel, in which are present the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 2% by weight.

Remarks

Applicants respectfully request that the foregoing amendments be entered prior to substantive examination of the application.

Respectfully submitted,
FAY, SHARPE, FAGAN
MINNICH & McKEE, LLP

Date: January 23, 2002

(Handwritten signature)
Scott A. McCollister
Reg. No. 33,961
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2518
(216) 861-5582

CERTIFICATE OF MAILING

I hereby certify that this PRELIMINARY AMENDMENT is being deposited with the United States Postal Service as EXPRESS MAIL in an envelope numbered EV 020233684 US, addressed to Assistant Commissioner for Patents, Washington, DC 20231 on January 23, 2002.

By: *(Handwritten signature)*
Georleen B. George